Pneumococcal conjugate vaccine for adults: “It's tough to make predictions,…”

Pletz Mathias W., Welte Tobias

Source: Eur Respir J 2015; 46: 1265-1268

Journal Issue: November

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Pletz Mathias W., Welte Tobias. Pneumococcal conjugate vaccine for adults: “It's tough to make predictions,…”. Eur Respir J 2015; 46: 1265-1268

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Pneumococcal vaccine: when, what, how and to whom Source: International Congress 2014 – MS06 What's new in pneumococcal vaccination? Year: 2014
Pneumococcal vaccination: current and future issues Source: Eur Respir J 2001; 18: 184-195 Year: 2001
Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population Source: Eur Respir J 2016; 48: 1492-1496 Year: 2016
Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013
Pneumococcal vaccination in bronchiectasis- an area for improvement? Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015
Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014
Pneumococcal vaccination Source: Eur Respir J 2005; 26: 982-983 Year: 2005
Pneumococcal vaccination practices and recommendations around the world Source: International Congress 2017 – Global challenges in respiratory medicine Year: 2017
The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012
Assessment of medical undergraduates’ relation to pneumococcal conjugate vaccine use Source: Virtual Congress 2021 – Medical education in respiratory medicine Year: 2021
Additive preventive effect of influenza and pneumococcal vaccines in elderly persons Source: Eur Respir J 2004; 23: 363-368 Year: 2004
Pneumococcal polysaccharide vaccination in COPD patients - some problems with antibody-response Source: Eur Respir J 2002; 20: Suppl. 38, 472s Year: 2002
Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018
Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands Source: Eur Respir J 2015; 46: 1407-1416 Year: 2015
Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis Year: 2017